Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645907 | 0.87 | NR1H4 (0.51) | NR1H4EPHX2TDP1RXRBESRRG | |
| SCHEMBL22388771 | 0.86 | NR1H4 (0.58) | NR1H4EPHX2TDP1RXRBESRRG | |
| SCHEMBL12203036 | 0.85 | TDP1 (0.56) | NR1H4EPHX2TDP1RXRBKDM4E | |
| SCHEMBL26804966 | 0.85 | NR1H4 (0.46) | NR1H4EPHX2TDP1ESRRGALDH1A1 | |
| SCHEMBL18130727 | 0.84 | NR1H4 (0.49) | NR1H4EPHX2TDP1RXRBESRRG | |
| SCHEMBL18130731 | 0.83 | ALDH1A1 (0.47) | NR1H4EPHX2TDP1ESRRGALDH1A1 | |
| SCHEMBL495839 | 0.83 | DGAT1 (0.55) | NR1H4EPHX2TDP1ESRRGALDH1A1 | |
| SCHEMBL283914 | 0.82 | KDM4E (0.65) | NR1H4EPHX2RXRBKDM4EALDH1A1 | |
| SCHEMBL19657820 | 0.82 | NR1H4 (0.51) | NR1H4EPHX2TDP1RXRBESRRG | |
| SCHEMBL31528338 | 0.82 | TDP1 (0.71) | NR1H4EPHX2TDP1RXRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585628-B | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-06 | — | — | US | disclosed |
| EP-4013759-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585628-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| US-20180194799-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194799-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007039142-A1 | C (2) -HETEROARYLMETHYL-C (4) -METHOXYMETHYL ACYL PYRROLIDINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITIS C VIRUS | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039143-A1 | C (2) -HETEROARYLMETHYL-C (4) -PYRAZIN-2-YL ACYL PYRROLIDINE COMPOUNDS AND THEIR USER FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITICS C (HCV) | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039142-A1 | C (2) -HETEROARYLMETHYL-C (4) -METHOXYMETHYL ACYL PYRROLIDINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITIS C VIRUS | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039143-A1 | C (2) -HETEROARYLMETHYL-C (4) -PYRAZIN-2-YL ACYL PYRROLIDINE COMPOUNDS AND THEIR USER FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITICS C (HCV) | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039145-A1 | C (2) -HETEROARYLMETHYL-C (4) -PYRAZINYL-2-YL ACYL PYRROLIDINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITIS C VIRUS | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039145-A1 | C (2) -HETEROARYLMETHYL-C (4) -PYRAZINYL-2-YL ACYL PYRROLIDINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITIS C VIRUS | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039144-A1 | PYRROLIDINE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | NR1H4 4173/4885EPHX2 2317/4885TDP1 334/4885 |
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NR1H4 89/4885EPHX2 3338/4885TDP1 4655/4885 |
| US-20180194799-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | BET1, PGGT1B, RABGGTB | NR1H4 1009/4885EPHX2 3545/4885TDP1 2918/4885 |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | NR1H4 2025/4885EPHX2 2325/4885TDP1 2716/4885 |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | NR1H4 4173/4885EPHX2 2317/4885TDP1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.